


**Fig. 6.** Impact of COVID-19 on pharmaceutical companies' (Sponsors') management of their clinical trials (%).  
COVID-19 = coronavirus disease 2019.



**Fig. 8.** COVID-19 clinical trial status worldwide (%). **(A)** Treatment/vaccine, **(B)** phase, **(C)** status, and **(D)** initiating party.

COVID-19 = coronavirus disease 2019, IIT = investigator initiated trial, NIH/US Fed = US National Institutes of Health or US Federal Reserve, SIT = sponsor initiated trial.